Cite
Ferreira JP, Collier T, Clark AL, et al. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. Eur Heart J Cardiovasc Pharmacother. 2021;doi: 10.1093/ehjcvp/pvab031.
Ferreira, J. P., Collier, T., Clark, A. L., Mamas, M. A., Rocca, H. B., Heymans, S., González, A., Ahmed, F. Z., Petutschnigg, J., Mujaj, B., Cuthbert, J., Rouet, P., Pellicori, P., Mariottoni, B., Cosmi, F., Edelmann, F., Thijs, L., Staessen, J. A., Hazebroek, M., Verdonschot, J., Rossignol, P., Girerd, N., Cleland, J. G., & Zannad, F. (2021). Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvab031
Ferreira, João Pedro, et al. "Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial." European heart journal. Cardiovascular pharmacotherapy vol. (2021). doi: https://doi.org/10.1093/ehjcvp/pvab031
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, González A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 02; doi: 10.1093/ehjcvp/pvab031. Epub 2021 Apr 02. PMID: 33822033.
Copy
Download .nbib